KRAS and lung carcinoma: Gefitinib sensitivity was examined in the lung cancer cell lines, H358 and A549, which express wild-type EGFR. Both cell lines express a mutant KRAS gene that is known as a marker of low sensitivity to EGFR inhibition and chemotherapy [24].